BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US04-10-2021
04-10-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings30-09-2021
Biocon gets 6 observations from USFDA for its Malaysian facility in pre-approval inspection
"We are confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the US FDA in the stipulated time," Biocon spokesperson said.27-09-2021
USFDA issues six observations post inspection of Biocon's Malaysian arm manufacturing facility
A Biocon spokesperson said the company is confident of addressing the observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA)25-09-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting24-09-2021
Biocon Call with Analysts on the new Biocon - Serum Institute Collaboration
Conference Call with Biocon Management and Analysts on the new Biocon SILS collaboration. Click on the pdf to read the full transcript. Management in attendance: Kiran Mazumdar Shaw, Adar Poonawalla.23-09-2021
Industry says UK's non-recognition of Indian vaccine certificates unfair'
India is the leading vaccine manufacturer for the world. Not recognising India's vaccine certificate is not acceptable, Dr Alok Roy, Chair of FICCI Health Services Committee, said. India's digital certification is far more reliable than other countries' manual systems, tweeted Kiran Mazumdar-Shaw, Chairperson of Biocon.23-09-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting22-09-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation-Q1 FY2221-09-2021